Cr | Istock | Getty Images Shares of Viking Therapeutics soared more than 80% in premarket trading Tuesday after the company’s experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could … Read more
In the wake of Nvidia‘s rapid ascension, CNBC’s Jim Cramer on Monday picked companies he thinks could have a chance at breaking $1 trillion in market capitalization. “There is no next Nvidia â it’s what we call at law school sui generis â and you might not see another story this strong for a generation,” … Read more
Vials move along a conveyor at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Monday, June 12, 2023. The success of Novo’s bestsellers Ozempic and Wegovy, drugs that help people lose significant amounts of weight, has created something of a gold rush in the pharma industry with about 40 companies developing products that … Read more
The following passage has been adapted from Jim Cramer’s opening monologue at Saturday’s annual meeting of the CNBC Investing Club. The single biggest issue we will be struggling with for the rest of the year is not how many Federal Reserve interest rate cuts we will have but whether the Fed can stand pat, or … Read more
Blood sample of patient positive tested for sickle cell. Kitsawet Saethao | Istock | Getty Images The approval of two gene therapies to treat sickle cell disease has given hope to patients who suffer from the debilitating disease, which overwhelmingly affects Black people and people of color. Health officials now face a challenge in finding … Read more
Wall Street’s whales turned on Alphabet . Hedge fund managers and billionaire investors alike lightened up on shares of the Google parent â or dumped them all together â in the fourth quarter of 2023, regulatory filings revealed. While backward-looking, these disclosures nevertheless shine a light on the moves influential investors have made. The sales … Read more
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. U.S. stocks declined Friday as investors interrupted hot inflation data. Investors weighed the odds that the Federal Reserve may take even longer to deliver interest rate cuts in 202, … Read more
Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite the hefty price tag â typically between $1,000 to $1,500 a month â consumers are clamoring for drugs like Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. This class of drugs, historically used to … Read more
It’s been hard to keep up. That’s the story of the big stock winners this year. They just keep winning and winning and winning. For analysts on Wall Street and here at the Club, it seems like some of these names are smashing through our six-to-nine-month price targets every few weeks. To that end, we’re … Read more
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible. Here’s Tuesday’s edition. A healthy break: … Read more
